Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
A novel series of CXCR4 antagonists were identified based on the substantial redesign of AMD070. These compounds possessed potent anti-HIV-1 activity and showed excellent pharmacokinetics in rat and dog.